Patent US5380523A successfully refreshed from Google Patents.
US5380523A
Expired / Lapsed
US
⏱️ 0.0 years remaining
High energy coprecipitate of nonoxynol oligomer, PVP and iodine having contraceptive and potent anti-HIV properties
Assignee: BOARD OF TRUSTEES OF UNNIVERSITY OF KENTUCKY
•
Filing: 1993-08-17
•
Granted: 1995-01-10
•
Expires: 2013-08-17
Abstract
Abstract A composition which is a contraceptive with potent anti-HIV activity. The composition is a high energy coprecipitate of nonoxynol-9 oligomers, polyvinylpyrrolidone (PVP) and iodine or PVP-I and shows a pronounced synergistic, anti-HIV effect between the compounds of the composition. A method of obtaining a contraceptive and anti-HIV environment in a female comprising administering to said female an effective amount of a high energy coprecipitate.
Inventors
- 👤 George A. Digenis
- 👤 Alexander G. Digenis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:37
CPC Classifications
D; D21; D21H; D21H21/00; D21H21/14; D21H21/36; A; A61; A61K; A61K31/00; A61K31/74; A61K31/785; A61K31/787; A61K31/79; A61K33/00; A61K33/18; A61K9/00; A61K9/14; A61K9/141; A61K9/146; Y; Y10; Y10S; Y10S424/00; Y10S424/14
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
58 words
A composition comprising a high energy coprecipitate of nonoxynol oligomer and polyvinylpyrrolidone polymer and iodine, or polyvinylpyrrolidone-iodine complex (PVP-I), wherein the combined effect of the compounds simultaneously precipitated in said high energy coprecipitate exceeds the individual effect of said compounds, and wherein said high energy coprecipitate has antiviral activity against human immunodeficiency virus-1 (HIV-1) in an MT-2 assay.
Claim 2
Dependent Claim
58 words
A composition comprising a high energy coprecipitate of nonoxynol oligomer and polyvinylpyrrolidone polymer and iodine, or polyvinylpyrrolidone-iodine complex (PVP-I), wherein the combined effect of the compounds simultaneously precipitated in said high energy coprecipitate exceeds the individual effect of said compounds, and wherein said high energy coprecipitate has antiviral activity against human immunodeficiency virus-1 (HIV-1) in an MT-2 assay.
Claim 3
Dependent Claim
12 words
A composition according to claim 1, wherein said coprecipitate is a powder.
Claim 4
Dependent Claim
15 words
A composition according to claim 2, wherein said powder is a finely divided crystalline powder.
Claim 5
Dependent Claim
15 words
A composition according to claim 1, wherein said PVP-I comprises about 0.09-9.4% w/w of iodine.
Claim 6
Dependent Claim
26 words
A composition according to claim 1, wherein said PVP-I comprises an antiviral concentration of free iodine of about 0.03% w/v or 300 ppm complexed with PVP.
Claim 7
Dependent Claim
29 words
A composition according to claim 1, wherein said PVP-I comprises an effective antiviral concentration of free iodine of about 0.0094 w/v of iodine or 94 ppm complexed with PVP.
Claim 8
Dependent Claim
23 words
A composition according to claim 1, wherein said nonoxynol oligomer of said coprecipitate comprises from about 5.8 to 11.8% w/w of nonoxynol-9 oligomer.
Claim 9
Dependent Claim
34 words
A composition according to claim 1, wherein said coprecipitate is present at a concentration of about 3.24 mg/ml of PVP-I and about 0.2 mg/ml of N-9 oligomer of an average molecular weight of 599.
Claim 10
Dependent Claim
32 words
A composition according to claim 1, wherein said coprecipitate is present at a concentration of about 5.8 mg/ml PVP-I and about 0.2 mg/ml N-9 oligomer of an average molecular weight of 306.
Claim 11
Dependent Claim
32 words
A composition according to claim 1 wherein said coprecipitate is present at a concentration of about 5.8 ppm of N-9 oligomer and about 940 ppm of PVP-I or 94 ppm of iodine.
Claim 12
Dependent Claim
20 words
A composition of claim 1, wherein said nonoxynol oligomer is an nonoxynol-9 oligomer with an average molecular weight of 599.
Claim 13
Dependent Claim
31 words
A composition of claim 1, wherein said nonoxynol oligomer is nonoxynol-9 oligomer comprising oligomers of N-9 having a range of molecular weight of each oligomer from about 264 to about 1000.
Claim 14
Dependent Claim
17 words
A composition of claim 1, wherein the percent of polyvinylpyrrolidone ranges from about 88% to about 97%.
Claim 15
Dependent Claim
19 words
A composition of claim 1, wherein the average molecular weight of said polyvinylpyrrolidone ranges from about 2,500 to 1,100,000.
Claim 16
Dependent Claim
85 words
A method of preparing a composition according to claim 1, comprising the steps of: (a) fractionating commercially available spermicide nonoxynol-9 (N-9) to seventeen oligomers by high pressure liquid chromatography (HPLC); (b) adding an N-9 oligomer obtained in step (a) with a 10% or 1% solution w/v of PVP-I in a solvent, (c) placing the product of step (b) in an oil bath at about 100° C., and allowing the solvent to evaporate; and (d) obtaining a high energy coprecipitate of N-9, polyvinylpyrrolidone (PVP) and iodine.
Claim 17
Dependent Claim
49 words
A method of achieving a contraceptive and anti-HIV in environment the vaginal cavity of a female comprising administering to said vaginal cavity of said female an effective amount of a composition according to claim 1 to achieve a contraceptive and anti-HIV in environment the vaginal cavity of said female.
Claim 18
Dependent Claim
26 words
The method according to claim 16, wherein said coprecipitate is administered in a form selected from the group consisting of tablets, capsules, ointments, creams and suppositories.
Claim 19
Dependent Claim
25 words
The method according to claim 16, wherein said effective amount of said coprecipitate comprises from about 6-12% w/v N-9 and about 0.09-9% w/v of PVP-I.
References Cited (Backward Citations)
US4317447A
Cited
US4297341A
Cited
US4299759A
Cited
US4954351A
Cited
US4707362A
Cited
US4775638A
Cited
US4923677A
Cited
US4925033A
Cited
US5070889A
Cited
US5156164A
Cited
US5073365A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-01-09 | 1998-07-11 | 1999-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-01-09 | 2002-07-11 | 2003-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-01-09 | 2006-07-11 | 2007-01-10 | $7700.00 | Window Closed / Lapsed |